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Objectives: We assessed available data on impact of partial external biliary diversion 
(PEBD) surgery on clinical outcomes in patients with progressive familial intrahepatic 
cholestasis (PFIC).  
Methods: We performed a systematic literature review (PubMed) and meta-analysis to 
evaluate relationships between liver biochemistry parameters (serum bile acids, bilirubin, and 
alanine aminotransferase [ALT]) and early response (pruritus improvement) or long-term 
outcomes (need for liver transplant) in patients with PFIC who underwent PEBD.  
Results: Searches identified 175 publications before September 2018; 16 met inclusion 
criteria. Receiver operating characteristic (ROC) analysis examined ability of liver 
biochemistry parameters to discriminate patients who demonstrated early and long-term 
response to PEBD from those who did not. Regarding pruritus improvement in 155 included 
patients in aggregate, 104 (67%) were responders, 14 (9%) had partial response, and 37 
(24%) were non-responders. In ROC analyses of individual patient data, post-PEBD serum 
concentration of bile acids, in particular, could discriminate responders from non-responders 
for pruritus improvement (area under the curve, 0.99; p<0.0001; n=42); to a lesser extent, this 
was also true for bilirubin (0.87; p=0.003; n=31), whereas ALT could not discriminate 
responders from non-responders for pruritus improvement (0.74; p=0.06; n=28). Reductions 
from pre-PEBD values in serum bile acid concentration (0.89; p=0.0003; n=32) and bilirubin 
(0.98; p=0.002; n=18) but not ALT (0.62; p=0.46; n=18) significantly discriminated 
decreased aggregate need for liver transplant. 
Conclusions: Changes in bile acids seem particularly useful in discriminating early and long-
term post-PEBD outcomes and may be potential biomarkers of response to interruption of 
enterohepatic circulation in patients with PFIC. 
 
Keywords: cholestasis; intrahepatic cholestasis; pediatrics; bile acids 
What Is Known 
 In progressive familial intrahepatic cholestasis (PFIC), disruptions in bile acid 
transportation lead to progressive and often life-threatening liver disease. 
 Surgical interventions include interruption of enterohepatic circulation via partial 
external biliary diversion (PEBD). 
 
What Is New 
 In this meta-analysis, we evaluated relationships between liver biochemistry 
parameters on the one hand and early response (pruritus improvement) and long-term 
outcomes (need for liver transplant) on the other in patients with PFIC who underwent 
PEBD. 
 Our findings suggest that bile acids and bilirubin levels may be useful as potential 
biomarkers in predicting both early response and long-term outcomes after PEBD. 
  
INTRODUCTION   
Progressive familial intrahepatic cholestasis (PFIC) is a family of ultra-rare inherited 
disorders characterized by disrupted bile homeostasis, debilitating pruritus, elevated serum 
bile acid levels, and potentially fatal liver disease.
1-6
 Pathologies underlying PFIC include 
deficiencies in familial intrahepatic cholestasis 1 protein (FIC1), bile salt export pump 




Currently, there are no approved medical treatments for patients with PFIC.
1
 Treatments used 
off-label for symptom relief or to counter the detrimental effects of cholestasis include fat-
soluble vitamins, ursodeoxycholic acid (UDCA), cholestyramine, rifampicin, and 
antihistamines.
8
 However, medical treatment often fails, necessitating surgical intervention.
1
 
Surgical approaches include strategies to interrupt the enterohepatic circulation, such as 
partial external biliary diversion (PEBD), partial internal biliary diversion, ileal 
exclusion/bypass, or gallbladder-colonic bypass, and, in the most severe/advanced cases 
and/or upon failure of other treatments to sufficiently relieve symptoms, liver 
transplantation.
4,9,10
 In PEBD, which is commonly used in FIC1-deficient and BSEP-deficient 
PFIC but is not a standard treatment for MDR3-deficient PFIC, a jejunal conduit from the 
gallbladder to the abdominal wall partially diverts bile to a permanent stoma.
10
 PEBD 
surgery, if performed before advanced liver disease has developed, reduces serum bile acids 
and pruritus and can improve long-term outcomes in patients with PFIC.
9,11
 However, some 
patients experience complications related to the external stoma,
9,12
 and approximately 25% of 
patients with PFIC fail to respond to PEBD.
10
 Understanding the relationships between 
laboratory parameters and clinical responses/outcomes to therapeutic interventions would be 
valuable to assess whether potential biomarkers for short- or long-term outcomes would be 
useful for evaluating new treatment approaches in patients with PFIC. Unfortunately, 
available data are limited to small studies, case reports, and case series.  
 
Using data from published reports, this systematic literature review and meta-analysis 
assessed whether liver biochemistry parameters of serum bile acids, bilirubin, and alanine 
aminotransferase (ALT) could discriminate responders from non-responders for early 
responses (effect on pruritus) and long-term outcomes (death or decreased aggregate need for 
liver transplant) in PFIC patients who underwent PEBD. 
 
METHODS   
Literature Search  
The systematic literature search included studies reporting liver biochemistries and short- and 
long-term findings for patients with PFIC who underwent PEBD surgery. We searched 
PubMed for studies published before September 30, 2018 using the terms “biliary diversion” 
or “cholestasis.” Resulting publications were searched for the following: “external bile/biliary 
diversion” and “PFIC,” “progressive familial intrahepatic cholestasis,” or “Byler’s disease.” 
Other diagnoses (e.g., Alagille syndrome, biliary atresia) and procedures (e.g., internal bile 
diversion, ileal bypass, or ileal exclusion) were excluded. All studies reporting pre- and post-
PEBD liver biochemistry values (serum bile acids, bilirubin, and ALT) and ≥1 short- or long-
term clinical outcome were eligible for inclusion in the meta-analysis. Publications that 
reported results descriptively (e.g., “lowering” or “normalization”), without numerical values, 
were excluded.  
 
Meta-analysis 
The meta-analysis included all publications with extractable individual patient data. 
Consistently available liver biochemistry parameters are included in this report. It was 
assumed that the term bilirubin meant total serum bilirubin. In addition, authors of 
publications identified in the literature search were contacted to determine if they were 
willing and able to contribute individual data if only grouped data had been published. 
 
Receiver operating characteristic (ROC) analysis (SAS
®
 version 9.4 [SAS Institute Inc., 
Cary, NC] using PROC LOGISTIC) was conducted to assess whether liver biochemistry 
parameters could discriminate PFIC patients who demonstrated early and long-term 
responses to PEBD from those who did not. ROC curves based on liver biochemistry 
parameters were explored using post-PEBD levels, absolute reductions, and relative 
reductions (expressed as percentages, compared with pre-PEBD levels). The ability of each 
parameter to distinguish PEBD responders and non-responders was assessed based on 
statistical significance of the area under the ROC curve (AUC; null hypothesis: AUC=0.5).  
 
Responses to PEBD surgery were defined as “pruritus improvement” for early response and 
“decreased aggregate need for liver transplant” for long-term response. Despite no consistent 
definition for early response across all publications, pruritus improvement was considered an 
early response because all publications included pruritus improvement as at least part of the 
definition. When early response was based on multiple measures, “partial response” was 
defined as (at least) improvement in pruritus but not in all measures. To dichotomize results 
for the ROC analysis, partial responders were grouped with non-responders. Long-term 
responders were defined as patients who did not receive liver transplant and/or did not die in 




Literature Search  
PubMed searches identified 175 publications (Figure 1), of which, 16 met eligibility criteria 
and included pre- and post-PEBD liver biochemistry values and ≥1 clinical outcome in PFIC 
patients.
9,12-26
 Of these, 1 publication was excluded because patient liver biochemistry data 
could not be paired with clinical outcomes.
26
 An additional article
11
 was identified through 
review of an article by the same authors
22
 and was included because it provided additional 
long-term liver biochemistry data. This yielded a total of 16 publications eligible for meta-
analysis across 155 PFIC patients (Figure 1 and Table, Supplemental Digital Content 1, 
http://links.lww.com/MPG/B838). Median age at PEBD was 3 years (range: 5 months‒13 
years). Reports included PFIC patients with deficiencies in FIC1, BSEP, or MDR3; in many 
cases, underlying genotypes conferring PFIC disease were not disclosed or evaluated. 
Although not included in the original publication, individual liver biochemistry data were 
provided by authors for 1 study
22
 and were used in the current analysis (along with individual 
patient data from additional publications) in agreement with the authors and with ethical 
approval. 
 
Liver Biochemistry Parameters Before PEBD  
Based on aggregate and individual patient data, bile acids, bilirubin, and/or ALT were 
variable and substantially elevated before PEBD in patients with PFIC.  
 
Pre-PEBD Bile Acid Levels 
For pre-PEBD bile acid levels, results were available in 13/16 studies (142/155 patients). 
Across 6 studies (encompassing 100 patients with aggregate bile acid data), 3 reported pre-
PEBD levels as means (range, 249–307 mol/L)
13,14,17
 and 3 reported medians (range, 
299−346 mol/L)
9,15,16
 that were approximately 25 to 35 times the upper limit of normal 
(ULN) of 10 mol/L. Individual bile acid patient data were available for 42 patients across 7 
studies
18,19,21-25
 and were also elevated before PEBD (median [quartile 1; quartile 3 (Q1; 
Q3)], 259 [195; 344] mol/L; Figure, Supplemental Digital Content 2A, 
http://links.lww.com/MPG/B838). 
 
Pre-PEBD Bilirubin Levels 
For pre-PEBD bilirubin levels, results were available in 13/16 studies (118/155 patients). In 6 
studies with aggregate bilirubin data (encompassing 87 patients), 4 reported pre-PEBD levels 
as means (range, 8–75 mol/L)
12-14,17
 and 2 reported medians (33 and 41 mol/L).
9,16
 
Individual bilirubin patient data were available for 31 patients across 7 studies.
18-24
 Before 
PEBD, bilirubin was elevated well above the ULN (median [Q1; Q3], 76 [41; 115] mol/L; 
Figure, Supplemental Digital Content 2B, http://links.lww.com/MPG/B838). In general, 
pre-PEBD bilirubin levels were well above the ULN of 17 mol/L. 
 
Pre-PEBD ALT Levels 
For pre-PEBD ALT levels, results were available in 9/16 studies (82/155 patients). Across 4 
studies with aggregate ALT data (encompassing 54 patients), 2 reported ALT levels as means 
(38 and 96 U/L)
13,14
 and 2 reported medians (60 and 75 U/L).
9,16
 Individual patient data were 
available for 28 patients across 5 studies (1 patient was excluded due to lack of baseline 
data).
18-20,22,24
 Before PEBD, ALT was elevated well above the ULN of ~35 U/L in patients 
>2 years of age (n=28; median [Q1; Q3], 105 [54; 192] U/L; Figure, Supplemental Digital 
Content 2C, http://links.lww.com/MPG/B838). 
PEBD Surgery Early Response  
Post-PEBD follow-up times evaluating effects of PEBD on pruritus ranged from 6 months to 
3 years, although some publications reported pruritus improvement within days or 
weeks.
14,18,19,21
 Overall, 104 patients (67%) had an early response of pruritus improvement 
following PEBD, 14 (9%) showed a partial response, and 37 (24%) patients were non-
responders.  
 
PEBD Surgery Long-Term Response 
For long-term response (decreased aggregate need for liver transplant), 3 studies including 34 
PFIC patients who underwent PEBD reported individual patient data on liver biochemistry 
parameters and long-term outcomes.
11,24,25
 Median (range) follow-up duration was 2.5 (0.2–
10) years in the liver transplant group and 8 (0.5–13) years for those that did not receive liver 
transplant. In patients who underwent PEBD, 13 (38%) of 34 needed a liver transplant and/or 
died during follow-up (non-responders), and 21 (62%) did not receive liver transplant 
(responders). 
 
Relationship Between Liver Biochemistry Parameters and Early Response  
Relationships between liver biochemistry parameters (serum bile acids, total serum bilirubin, 
and ALT) and early response of pruritus improvement were examined using available 
individual patient data. 
 
Bile Acids/Early Response  
Seven studies with individual patient bile acid data for 42 patients evaluated pruritus 
improvement post-PEBD.
18,19,21-25
 Bile acid levels decreased in patients classified as 
responders (median [Q1; Q3] percent change, −98 [−99; −97]%; n=25), partial responders 
(−42 [−72; −32]%; n=5), and non-responders (−21 [−32; 34]%; n=12); absolute post-PEBD 
bile acid levels were generally lower in responders than partial or non-responders (Figure 
2A). In the ROC analysis, absolute post-PEBD bile acid levels could discriminate PFIC 
patients with an early response (i.e., improved pruritus) from those with partial or no 
response (AUC 0.99; p<0.0001; Figure 2B, Table 1). Absolute reduction (AUC 0.79; 
p=0.0017) and percentage reduction (AUC 0.98; p<0.0001) in bile acids following PEBD 
also could discriminate responders from partial and non-responders (Table 1).   
Bilirubin/Early Response  
Seven studies with individual patient bilirubin data for 31 patients evaluated pruritus 
improvement post-PEBD.
18-24
 Bilirubin levels decreased in patients classified as responders 
(median [Q1; Q3] percent change, −84 [−93; −60]%; n=24), in 1 partial responder (−30%; 
n=1), and in non-responders (−19 [−35; 41]%; n=6); absolute post-PEBD bilirubin levels 
were generally lower in responders than in partial or non-responders (Figure 2C). In the 
ROC analysis, absolute post-PEBD bilirubin levels could discriminate PFIC patients who 
demonstrated an early response of pruritus improvement from those with partial or no 
response (AUC 0.87; p=0.003; Figure 2D, Table 1). Absolute reduction (AUC 0.77; 
p=0.0335) and percentage reduction (AUC 0.83; p=0.007) in bilirubin levels following PEBD 
also could discriminate responders from partial and non-responders (Table 1).   
 
ALT/Early Response  
Five studies with individual patient ALT data for 28 patients evaluated pruritus improvement 
post-PEBD.
18-20,22,24
 ALT levels decreased in patients classified as responders (median [Q1; 
Q3] percent change, −51 [−75; 29]%; n=21) and in non-responders (−28 [−46; −10]%; n=6), 
with a small increase in 1 patient classified as a partial responder (+4%; n=1). Absolute post-
PEBD ALT levels were generally lower in responders than in non-responders (Figure 2E), 
but they did not significantly discriminate responders from partial and non-responders in the 
ROC analysis (AUC 0.74; p=0.06; Figure 2F). Likewise, absolute ALT reduction (AUC 
0.59; p=0.47) and percentage reduction (AUC 0.61; p=0.38) did not significantly discriminate 
responders from partial and non-responders (Table 1).   
 
Relationship Between Liver Biochemistry Parameters and Long-term Response  
Relationships between serum bile acids, total serum bilirubin, and ALT and long-term 
response of need for liver transplant were examined using available individual patient data. 
 
Bile Acids/Long-term Response 
Among 32 patients with available bile acid and long-term response data from 3 studies,
11,24,25
 
20 did not require liver transplant (responders) and 12 required liver transplant or died despite 
PEBD (non-responders) (Figure 3A). Median (Q1; Q3) post-PEBD bile acid levels were 6 
(4; 155) μmol/L (normalized in 12 patients) in responders and 258 (163; 298) μmol/L in non-
responders, representing median (Q1; Q3) percent changes of −98 (−99; −51)% and −28 
(−50; 17)%, respectively. This suggested that lower post-PEBD bile acid levels are found in 
responders than in non-responders (Figure 3A). In the ROC analysis, absolute post-PEBD 
bile acid levels could discriminate patients who demonstrated a long-term response to PEBD 
(i.e., those who did not require liver transplant) from those who required liver transplant or 
died despite PEBD (AUC 0.89; p=0.0003; Figure 3B) as did percentage reduction (AUC 
0.83; p=0.002) but not absolute reduction (Table 1).   
Bilirubin/Long-term Response  
Among the 18 patients with available bilirubin and long-term response data from 2 
studies,
11,24
 13 did not require liver transplant (responders) and 5 required liver transplant 
despite PEBD (non-responders) (Figure 3C). Median (Q1; Q3) post-PEBD bilirubin levels 
were 9 (8; 13) μmol/L in responders and 77 (77; 118) μmol/L in non-responders, representing 
median (Q1; Q3) percent changes of −92 (−93; −80)% and −33 (−35; −4)%, respectively. 
This suggested that in responders, post-PEBD bilirubin levels are lower than in non-
responders (Figure 3C). In the ROC analysis, absolute post-PEBD bilirubin levels could 
discriminate patients who did not require liver transplant from those who did despite PEBD 
(AUC 0.98; p=0.002; Figure 3D) as did absolute reduction (AUC 0.83; p=0.03) and 
percentage reduction (AUC 0.88; p=0.02) (Table 1).   
 
ALT/Long-term Response 
Among 18 patients with available ALT and long-term response data,
11,24
 13 did not undergo 
liver transplant (responders) and 5 underwent liver transplant despite PEBD (non-responders) 
(Figure 3E). Median (Q1; Q3) post-PEBD ALT levels were 80 (30; 122) U/L in responders 
(a reduction from pre-PEBD levels of 146 [58; 209] U/L) and 83 (68; 171) U/L in non-
responders (a reduction from pre-PEBD levels of 112 [52; 190] U/L), representing median 
(Q1; Q3) percent changes of −51 (−75; 4)% and −10 (−26; 15)%, respectively (Figure 3E). 
In the ROC analysis of ALT levels, absolute post-PEBD (AUC 0.62; p=0.46; Figure 3F), 
absolute change (AUC 0.68; p=0.26), and percentage change (AUC 0.68; p=0.26) did not 
discriminate patients with a long-term response to PEBD from non-responders (Table 1).   
 
DISCUSSION  
This systematic literature review and meta-analysis assessed available data on the impact of 
PEBD surgery on early and long-term outcomes in patients with PFIC. Our analyses indicate 
that PEBD reduces serum concentrations of bile acids and bilirubin, and that post-PEBD bile 
acid and bilirubin levels can discriminate responders from non-responders for both early 
responses (effect on pruritus) and long-term outcomes (aggregate need for liver transplant); 
post-PEBD ALT levels did not have this discriminatory ability. Our findings suggest that bile 
acid and bilirubin levels may be useful as potential biomarkers in predicting both early 
response and long-term outcomes after PEBD.  
 
Our findings that PEBD impacts liver biochemistry parameters and pruritus are generally 
consistent with data from other recent studies, although there may be some overlap between 
patients in our study and those discussed below. A recent retrospective multicenter study 
found that 81% (n=17/21) of FIC1-deficient patients and 76% (n=26/34) of BSEP-deficient 
patients reported pruritus improvement (partial or complete) after undergoing PEBD.
27
 Serum 
bile acid and bilirubin levels also decreased significantly after PEBD. In a retrospective 
analysis from the Childhood Liver Disease Research Network (ChiLDReN) that included 34 
patients with PFIC (FIC1 deficiency, n=16; BSEP deficiency, n=18),
28
 the proportion of 
patients reporting pruritus was significantly reduced following PEBD relative to pre-surgery 
values (65% vs 10% for FIC1-deficient patients; 50% vs 20% for BSEP-deficient patients; 
both p<0.0001). There was also a trend toward reduced bile acid levels in these patients. 
Total serum bilirubin decreased significantly in FIC1-deficient patients but not in BSEP-
deficient patients. No significant changes in ALT were observed. Two of 12 FIC1-deficient 
patients and 3 of 13 BSEP-deficient patients underwent liver transplant following PEBD. 
Unfortunately, neither study
27,28
 analyzed relationships between bile acid or other serum 
parameter levels and clinical outcomes.  
 
A recent retrospective follow-up study from the NAPPED (Natural Course and Prognosis of 
PFIC and Effect of Biliary Diversion) consortium found that native liver survival was 
significantly higher in BSEP-deficient patients who had undergone biliary diversion surgery 
than those who had not,
29
 and a significant association was identified between lower post-




Although the long-term benefits of PEBD are established in patients with PFIC, limitations 
such as need for a permanent stoma have spurred exploration of alternative surgical methods, 
including ileal exclusion and partial internal biliary diversion.
8,16
 At present, only a few 
reports are available that describe long-term results of these procedures, and the number of 
patients is low.
8,31,32
 The ileal bile acid transporter (IBAT) is a potential therapeutic target in 
patients with PFIC because it mediates resorption of 95% of intestinal bile acids,
33,34
 and 
IBAT inhibition represents a novel medical approach to interrupt the enterohepatic 
circulation. Our meta-analysis suggests that reductions in serum bile acids following 
interruption of enterohepatic circulation via PEBD can discriminate PFIC patients with 
pruritus improvement versus those without improvement, which could be useful for 
evaluating IBAT inhibitors like odevixibat (A4250) and maralixibat. In a phase 2 study of 
children with cholestatic liver disease that included 13 children with PFIC, reductions in 
serum bile acids significantly correlated with reductions in pruritus following odevixibat 
treatment.
35
 An interim analysis of a phase 2 study in children with PFIC showed an overall 




Findings of our meta-analysis, together with studies describing interventions that interrupt 
enterohepatic circulation, such as PEBD or IBAT inhibition, provide insight into 
relationships between liver biochemistry parameters (e.g., bile acids) and outcomes (e.g., 
pruritus improvement, need for liver transplant, death) in children with intrahepatic 
cholestasis; future studies that better define these relationships are warranted. 
 
This study has some limitations, including a retrospective design with limited access to raw 
and/or individual patient data. In addition, there were no uniform definitions for patient 
selection criteria or for early or long-term response based on validated rating scales. Pruritus 
is difficult to quantify objectively because it involves physical sensations and emotional 
responses; therefore, this analysis utilized the responder categorization approach. Also, 
patients could not be analyzed by PFIC subgroup due to lack of information, including 
genotype data. Variability in surgical skill and experience as well as varying surgical 
approaches to PEBD and criteria/indications for choosing liver transplant may have 
contributed to differences in outcomes. There is a potential bias for publishing successful 
versus unsuccessful surgical reports. Finally, a relatively small number of patients was 
included in some analysis subgroups, and we cannot completely exclude the possibility that 
some patients included in this analysis were present in duplicate across utilized publications, 
as patient identities were not disclosed; this could reduce the number of unique patients in the 
current analysis. We also cannot exclude the possibility that additional studies fitting the 
search criteria may have been identified in other databases such as EMBASE or the Cochrane 
Central Register of Controlled Trials. Additional research is needed to confirm results of this 
meta-analysis, including future studies investigating additional tools for evaluating the effects 
of therapeutic interventions for PFIC. 
 
In conclusion, this meta-analysis of PEBD outcomes in patients with PFIC found that 
changes in bile acids and bilirubin were potential biomarkers for predicting early and long-
term outcomes after PEBD. We speculate these parameters could also be utilized 
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Figure 1. Diagram of Screening and Selection of Included Studies. 
a
One publication that 
contained long-term outcomes but lacked liver biochemistry data
11
 was added because it was 
found to be a follow-up to an article already included in the literature search that included 





Figure 2. Post-PEBD Levels of Liver Biochemistry Parameters and Early Response 
(Pruritus Improvement). A) Post-PEBD bile acid levels in 42 patients grouped as 
responders, partial responders, and non-responders from 7 studies.
18,19,21-25
 B) ROC curve for 
post-PEBD serum bile acid levels and pruritus improvement. C) Post-PEBD bilirubin levels 
in 31 patients grouped as responders, partial responders, and non-responders from 7 
studies.
18-24
 D) ROC curve for post-PEBD serum bilirubin levels and pruritus improvement. 
E) Post-PEBD ALT levels in 28 patients grouped as responders, partial responders, and non-
responders from 5 studies.
18-20,22,24
 F) ROC curve for post-PEBD serum ALT levels and 
pruritus improvement. Solid horizontal bars indicate the median value for each group; dotted 
horizontal lines indicate upper limit of normal. ALT, alanine transaminase; AUC, area under 




Figure 3. Post-PEBD Levels of Liver Biochemistry Parameters and Long-term 
Response (Decreased Need for Liver Transplant). A) Post-PEBD bile acid levels in 32 
patients grouped as responders and non-responders from 3 studies.
22,24,25,a
 B) ROC curve for 
post-PEBD serum bile acid levels and decreased aggregate need for liver transplant. C) Post-
PEBD bilirubin levels in 18 patients grouped as responders and non-responders from 2 
studies.
22,24,a
 D) ROC curve for post-PEBD serum bilirubin levels and decreased aggregate 
need for liver transplant. E) Post-PEBD ALT levels in 18 patients grouped as responders and 
non-responders from 2 studies.
22,24,a
 F) ROC curve for post-PEBD serum ALT levels and 
decreased aggregate need for liver transplant. Solid horizontal bars indicate median value for 
each group; dotted horizontal lines indicate upper limit of normal. 
a
Biochemistry data from 
Arnell 2008
22
; long-term response data from Arnell 2010.
11
 ALT, alanine transaminase; 
AUC, area under the ROC curve; NS, not significant; PEBD, partial external biliary 
diversion; ROC, receiver operating characteristic; SD, standard deviation.  
 
  
Table 1. Ability of Liver Biochemistry Parameters to Discriminate Responders from 
Non-Responders: Early and Long-term Responses  
ROC Analysis Bile Acids 
AUC, p Value 
Bilirubin 
AUC, p Value 
ALT 
AUC, p Value 
Early response (pruritus improvement) 
Patients, n 42 31 28 






















Long-term response (decreased need for liver transplant) 
Patients, n 32 18 18 























Reductions from pre-PEBD levels. 
ALT, alanine transaminase; AUC, area under the ROC curve; PEBD, partial external biliary 
diversion; ROC, receiver operating characteristic. 
 
